| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3257081 | Clinical Immunology | 2012 | 6 Pages |
Laquinimod is a novel, orally administered immune-modulatory molecule in advanced phase clinical trials in relapsing–remitting multiple sclerosis. Experimental evidence to date, derived mostly from animal models of multiple sclerosis, suggests that laquinimod may mediate its effects via modulating pro-inflammatory immune responses and interfering with cell trafficking, as well as potentially acting directly in the central nervous system to limit demyelination and axonal injury. The clinical trial results to date have established efficacy on imaging markers of disease activity and have shown a favorable safety and tolerability profile. If phase III studies confirm clinical efficacy and safety, laquinimod would represent a welcome new option in the treatment of multiple sclerosis.
